Tern updates on portfolio company Device Authority

TERN

Tern Plc (LON:TERN), the investment company specialising in supporting high growth, early-stage, disruptive Internet of Things (IoT) technology businesses, has announced an update in relation to Device Authority Limited, a company in which Tern has a 30.0% equity holding.

The remaining Tranche Two of the Device Authority Fundraising of US$3.3 million, by Ten Eleven Ventures was, as announced on 27 December 2023, due to be completed on or prior to 30 September 2024.  Due to the positive current performance of Device Authority, it has been agreed by the Device Authority board to defer the completion of Tranche Two to, if required, on or before 31 December 2024.

Tern’s holding in Device Authority therefore remains unchanged at 30.0% (before any dilution on exercise of share options or the potential completion of Tranche Two), with this holding having an unaudited book valuation of approximately US$5.4 million (approximately £4.2 million), as announced on 9 August 2024.

Unless otherwise stated, defined terms should be given the meaning given to them in the Company’s announcement made on 27 December 2023.

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Tern plc raises £450,000 in share placing ahead of AIM admission

Tern plc has raised £450,000 through a placing and outlined expected admission timing and updated voting rights.

Search